Due to increasing research on molecular tumor markers and NCLC-driven genes, rapid development of the anti-epidermal growth factor receptor (EGFR)-targeted therapy could effectively control NSCLC progression in patients with active mutation or amplification of EGFR-driven tumor and increased patient survival [7–17]. Here, EGFR is linked to neoplasm.